Best of ASCO - 2014 Annual Meeting

 

Welcome

Molecular Diagnostics and Imaging

Tumor Biology

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
[18F]FET-βAG-TOCA versus [68Ga]DOTATATE PET/CT in functional imaging of neuroendocrine tumours.

Suraiya Rahim Dubash

e24193

A cell cycle-related RNA expression signature of neoantigen burden in lung adenocarcinoma.

Michael F Sharpnack

12072

A sensitive and accurate test for simultaneous detection of 36 BRAF and NRAS mutations.

Nancy Patten

e24153

Analysis of tumor samples from SOLO2: Concordance of BRCA mutation (BRCAm) detection in tumor vs. blood and frequency of BRCA-specific loss of heterozygosity (LOH) and loss of function somatic mutations.

Darren R. Hodgson

12017

Analytical validation of the Oncomine Immune Response Research Assay (OIRRA) in a CLIA and CAP regulated laboratory for formalin fixed, paraffin embedded (FFPE) solid tumor specimens.

John Williamson

e24200

Application of a real world endpoint to identify and characterize genetic profiles of patients (pts) with poor prognosis in advanced non-small-cell lung cancer (aNSCLC).

Gracy Crane

12006

Barriers to tumor mutation burden (TMB) testing in NSCLC patients in the US and EU.

William H Angel

e24192

B-cell enrichment for next generation sequencing (NGS): An approach to detect actionable low frequency variants in B-cell lymphomas.

Maya P Panjikaran

e24165

Clinical significance of enterocyte-specific gene polymorphisms as candidate marker of oxaliplatin-based treatment for metastatic colorectal cancer.

Mitsukuni Suenaga

12066

Clinical targeted next-generation sequencing to identify potentially actionable alterations in the majority of Asian cancer patients.

Song Ling Poon

e24163

Clinical utility of next-generation sequencing (NGS)-based genomic profiling of advanced solid tumors in routine clinical practice.

Pramod Kumar Julka

e24157

Clinical utility of reflex testing using focused next generation sequencing for management of patients with advanced lung adenocarcinoma.

Navid Sadri

e24199

Comparative genomic profiling of distant metastatic and nondistant metastatic lung adenocarcinoma.

Henghui Zhang

e24182

Comparison of the prognostic performance between OncoMasTR and OncotypeDX multigene signatures in hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.

Catherine Margaret Kelly

12074

Comparison of the tumor mutation burden (TMB) analysis results between a targeted next-generation sequencing method and the conventional WES method.

Yuhang Cai

e24186

Comprehensive detection of targetable fusions in lung adenocarcinomas by complementary targeted DNAseq and RNAseq assays.

Ryma Benayed

12076

Computer-extracted stromal features of African-Americans versus Caucasians from H&E slides and impact on prognosis of biochemical recurrence.

Hersh Kumar Bhargava

12075

Confounding effects of clonal hematopoiesis in clinical genomic profiling of solid tumors.

Ahmet Zehir

12004

Construction and analysis of a novel pseudogene-associated ceRNA network to identify potential pseudogene signature for diagnosis and prognosis of human triple-negative breast cancer.

Yuan Li

e24167

Construction of a control database for the filtering of germline mutations and false positive mutations in the detection of tumor somatic variations.

Yuhang Cai

e24188

Detection of clinically relevant gene fusions in plasma samples of lung cancer patients in routine molecular diagnostics.

Anna Streubel

e24191

Development and validation of ColoScape: A new colorectal cancer mutation detection assay.

Michael Joseph Powell

e24189

Development of an NGS assay to detect MRD in hematologic malignancies.

James Yu

e24177

Efficacy of a structured workflow for the interpretation of comprehensive genomic analysis data in clinical routine.

Damian Tobias Rieke

e24164

Evolution of precision oncology treatment options over time.

Bat-Ami Gordon

e24179

Genomic profiling of carcinomas of unknown primary (CUP) to support clinical decisions.

Alwin Krämer

e24162

Getting consistent results from comparative analysis of RNA_Seq data from single patients.

Holly Beale

e24194

High concordance in advanced cancer patient paired testing by commercially available tumor tissue NGS assays and a liquid biopsy NGS assay.

Rebecca Christian Arend

e24169

Histology of Rosai-Dorfman disease in a subset of patients with Erdheim-Chester disease: A distinct entity mainly driven by MAP2K1.

Jerome Razanamahery

e24180

Hyperpolarized C-13 pyuvate metabolic MR imaging of solid tumor liver metastases as a biomarker of PI3K/mTOR pathway activity.

Rahul Raj Aggarwal

e24168

Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired commercial next-generation sequencing assays.

Catherine Callaghan Coombs

12068

Imaging of tumor infiltrating T cells with an anti-CD8 minibody (Mb) 89Zr-IAB22M2C, in advanced solid tumors.

Michael A. Postow

e24160

Impact and diagnostic gaps of multiplex genomic profiling (MGP) in an academic community-based cancer center.

Aditi Puri Singh

e24154

Impact of imaging based sarcopenia and modified advanced lung cancer inflammation index (mALI) on clinical outcomes in advanced NSCLC: A occult killer and a prognostic biomarker.

Abhishek Mahajan

e24166

Implementation of the genereader NGS system in a molecular pathology laboratory.

Andreas Bösl

e24175

Longitudinal ctDNA analysis to enable early assessment of prognosis in lung adenocarcinoma in the absence of matched tissue biopsy.

Xiaoju Max Ma

12077

Molecular profiles of endometrial cancers in a Caribbean black population.

Yi-Chun Lee

e24152

Molecular subtypes of triple-negative breast cancer (TNBC) tumor samples obtained before and after neoadjuvant systemic therapy (NST) and relationship between immunomodulatory (IM) gene signature and intensity of tumor-infiltrating lymphocytes (TILs).

Hiroko Masuda

12069

NGS for cancer testing: A clinical laboratory’s perspective.

Yassmine Akkari

e24158

Non-invasive in vivo prediction of tumour grade and IDH mutation status in gliomas using dynamic susceptibility contrast (DSC) perfusion- and diffusion-weighted MRI.

Sotirios Bisdas

e24173

Novel platform for monitoring bladder cancer recurrence using expression analysis of small non-coding RNAs.

Ilija Aleksic

12070

Phase 0/1 of positron emission tomography (PET) imaging agent [18F]-ODS2004436 as a marker of EGFR mutation in patients with non-small cell lung cancer (NSCLC).

Alexandre Cochet

e24184

Plasma sequencing of ctDNA in early stage breast cancer as part of the screening process.

Begona Jimenez Rodriguez

12073

Poly-ligand profiling (PLP) to differentiate pancreatic cancer patients who benefit from gemcitabine+evofosfamide versus gemcitabine+placebo treatment.

Valeriy Domenyuk

12067

Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study.

Charles Swanton

12003

Prognostic value of CXLC 9 in patients undergoing neoadjuvant radiochemotherapy and surgery in stage IIIA NSCLC.

Wolfgang Parsch

e24156

Refining actionable HER2 alterations in lung cancers through next generation sequencing (NGS).

Chongrui Xu

e24181

Relationship of miR-140-5p expression and p53 function and contribution to prognosis prediction and treatment decision of patients with gastric cancer.

Meng Xie

e24185

Resolving diagnostic uncertainty in bone-predominant metastases in cancer of unknown primary (CUP) using the 92-gene assay.

Kanwal Pratap Singh Raghav

12064

RNA sequencing for the detection of MET exon 14 skipping in specimens with splice-site mutations.

Parth Sitlani

e24178

Role of tumor profiling in rural oncology.

Ajaz Bulbul

e24183

Survival of patients treated by a Precision Oncology approach is determined by performance status and lines of therapy.

Bat-Ami Gordon

12071

Technical validation of the electric field-induced release and measurement (EFIRM) assay for the detection of EGFR mutations in circulating cell free DNA in plasma and saliva.

Fang Wei

e24172

The role of diffusion tensor imaging for non-invasive IDH phenotyping in gliomas.

Diana Roettger

e24174

The role of dynamic susceptibility contrast perfusion- weighted MRI in the estimation of IDH mutation in gliomas.

Sotirios Bisdas

12063

Towards enhancing the specificity of precision medicine assays.

Donald Joseph Johann

e24170

Upfront next generation sequencing in NSCLC: A publicly funded perspective.

Kirstin Perdrizet

12062

Validation of a new diagnostic platform for prostate cancer using expression profiling of small non-coding RNAs.

Winnie Wang

e24151

Whole genome sequencing in metastatic breast cancer: Lessons learned from the BC Cancer personalized oncogenomics program.

Nathalie LeVasseur

12065